2003
DOI: 10.1016/s0899-9007(03)00165-5
|View full text |Cite
|
Sign up to set email alerts
|

Soluble tumor necrosis factor-α receptor type 1 during selenium supplementation in psoriasis patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
11
0

Year Published

2008
2008
2020
2020

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 19 publications
(12 citation statements)
references
References 20 publications
0
11
0
Order By: Relevance
“…Selenium deficiency is reported to be one of the risk factors which could lead to susceptibility to inflammatory skin diseases [ 31 33 ]. An ample amount of studies are available showing low serum Se concentration in psoriasis patients [ 6 , 34 , 35 ]. Kadry et al have found that plasma Se levels were lower, osteopontin levels were extremely higher in the patient group compared to the control group and proposed that over-expression of osteopontin and low Se levels could be associated with the pathogenesis of psoriasis [ 36 ].…”
Section: Discussionmentioning
confidence: 99%
“…Selenium deficiency is reported to be one of the risk factors which could lead to susceptibility to inflammatory skin diseases [ 31 33 ]. An ample amount of studies are available showing low serum Se concentration in psoriasis patients [ 6 , 34 , 35 ]. Kadry et al have found that plasma Se levels were lower, osteopontin levels were extremely higher in the patient group compared to the control group and proposed that over-expression of osteopontin and low Se levels could be associated with the pathogenesis of psoriasis [ 36 ].…”
Section: Discussionmentioning
confidence: 99%
“…In another case-control study by Serwin et al, 22 patients received topical 5% salicylic acid ointment, 0.1% to 0.3% dithranol ointment, and 200 μg daily selenomethionine versus placebo for 4 weeks 38 . Both groups achieved almost complete remission, but the PASI score was higher in the selenium group (p < 0.05) and the TNF level was also higher in the selenium group.…”
Section: Resultsmentioning
confidence: 99%
“…At the end of the trial, PASI scores decreased from 14.68 ± 7.97 to 4.30 ± 3.92 and from 11.85 ± 6.73 to 1.67 ± 1.17 (P < 0.05) in those receiving selenomethionine and placebo, respectively. 25 In another study by Serwin et al, patients with plaque psoriasis receiving narrowband ultraviolet B (NB-UVB) therapy and either 200 μg selenomethionine or placebo showed similar reductions in mean PASI scores. 26 Harvima et al also found that selenium supplementation is not effective in treating psoriasis.…”
Section: Seleniummentioning
confidence: 99%